Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release